338 related articles for article (PubMed ID: 11121055)
1. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.
Yu K; Herr AB; Waksman G; Ornitz DM
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14536-41. PubMed ID: 11121055
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
Ibrahimi OA; Eliseenkova AV; Plotnikov AN; Yu K; Ornitz DM; Mohammadi M
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7182-7. PubMed ID: 11390973
[TBL] [Abstract][Full Text] [Related]
3. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand.
Anderson J; Burns HD; Enriquez-Harris P; Wilkie AO; Heath JK
Hum Mol Genet; 1998 Sep; 7(9):1475-83. PubMed ID: 9700203
[TBL] [Abstract][Full Text] [Related]
4. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.
Tanimoto Y; Yokozeki M; Hiura K; Matsumoto K; Nakanishi H; Matsumoto T; Marie PJ; Moriyama K
J Biol Chem; 2004 Oct; 279(44):45926-34. PubMed ID: 15310757
[TBL] [Abstract][Full Text] [Related]
5. Negative autoregulation of fibroblast growth factor receptor 2 expression characterizing cranial development in cases of Apert (P253R mutation) and Pfeiffer (C278F mutation) syndromes and suggesting a basis for differences in their cranial phenotypes.
Britto JA; Moore RL; Evans RD; Hayward RD; Jones BM
J Neurosurg; 2001 Oct; 95(4):660-73. PubMed ID: 11596961
[TBL] [Abstract][Full Text] [Related]
6. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities.
Ibrahimi OA; Zhang F; Eliseenkova AV; Itoh N; Linhardt RJ; Mohammadi M
Hum Mol Genet; 2004 Oct; 13(19):2313-24. PubMed ID: 15282208
[TBL] [Abstract][Full Text] [Related]
7. Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes.
Yu K; Ornitz DM
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3641-3. PubMed ID: 11274381
[No Abstract] [Full Text] [Related]
8. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity.
Ibrahimi OA; Zhang F; Eliseenkova AV; Linhardt RJ; Mohammadi M
Hum Mol Genet; 2004 Jan; 13(1):69-78. PubMed ID: 14613973
[TBL] [Abstract][Full Text] [Related]
9. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome.
Wilkie AO; Slaney SF; Oldridge M; Poole MD; Ashworth GJ; Hockley AD; Hayward RD; David DJ; Pulleyn LJ; Rutland P
Nat Genet; 1995 Feb; 9(2):165-72. PubMed ID: 7719344
[TBL] [Abstract][Full Text] [Related]
10. Craniosynostosis and related limb anomalies.
Wilkie AO; Oldridge M; Tang Z; Maxson RE
Novartis Found Symp; 2001; 232():122-33; discussion 133-43. PubMed ID: 11277076
[TBL] [Abstract][Full Text] [Related]
11. Presence of the Apert canonical S252W FGFR2 mutation in a patient without severe syndactyly.
Passos-Bueno MR; Richieri-Costa A; Sertié AL; Kneppers A
J Med Genet; 1998 Aug; 35(8):677-9. PubMed ID: 9719378
[TBL] [Abstract][Full Text] [Related]
12. Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model.
Morita J; Nakamura M; Kobayashi Y; Deng CX; Funato N; Moriyama K
Dev Dyn; 2014 Apr; 243(4):560-7. PubMed ID: 24259495
[TBL] [Abstract][Full Text] [Related]
13. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain.
Robertson SC; Meyer AN; Hart KC; Galvin BD; Webster MK; Donoghue DJ
Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4567-72. PubMed ID: 9539778
[TBL] [Abstract][Full Text] [Related]
14. FGFR2 mutation in a patient with Apert syndrome associated with humeroradial synostosis.
Kanauchi Y; Muragaki Y; Ogino T; Takahara M; Tsuchida H; Ishigaki D
Congenit Anom (Kyoto); 2003 Dec; 43(4):302-5. PubMed ID: 15041782
[TBL] [Abstract][Full Text] [Related]
15. [From gene to disease; craniosynostosis syndromes due to FGFR2-mutation].
van Ravenswaaij-Arts CM; van den Ouweland AM; Hoogeboom AJ; Herbergs J; Pals G
Ned Tijdschr Geneeskd; 2002 Jan; 146(2):63-6. PubMed ID: 11820058
[TBL] [Abstract][Full Text] [Related]
16. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis.
Yin L; Du X; Li C; Xu X; Chen Z; Su N; Zhao L; Qi H; Li F; Xue J; Yang J; Jin M; Deng C; Chen L
Bone; 2008 Apr; 42(4):631-43. PubMed ID: 18242159
[TBL] [Abstract][Full Text] [Related]
17. Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex.
Wang F; Lu W; McKeehan K; Mohamedali K; Gabriel JL; Kan M; McKeehan WL
Biochemistry; 1999 Jan; 38(1):160-71. PubMed ID: 9890894
[TBL] [Abstract][Full Text] [Related]
18. Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses.
Passos-Bueno MR; Sertié AL; Richieri-Costa A; Alonso LG; Zatz M; Alonso N; Brunoni D; Ribeiro SF
Am J Med Genet; 1998 Jul; 78(3):237-41. PubMed ID: 9677057
[TBL] [Abstract][Full Text] [Related]
19. Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity.
Chellaiah A; Yuan W; Chellaiah M; Ornitz DM
J Biol Chem; 1999 Dec; 274(49):34785-94. PubMed ID: 10574949
[TBL] [Abstract][Full Text] [Related]
20. De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome.
Oldridge M; Zackai EH; McDonald-McGinn DM; Iseki S; Morriss-Kay GM; Twigg SR; Johnson D; Wall SA; Jiang W; Theda C; Jabs EW; Wilkie AO
Am J Hum Genet; 1999 Feb; 64(2):446-61. PubMed ID: 9973282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
